Replaces reactive hydrogens to form t-BDMS derivatives Derivatization is usually complete upon dissolution with this exceptionally strong, yet mild …

Replaces reactive hydrogens to form t-BDMS derivatives Derivatization is usually complete upon dissolution with this exceptionally strong, yet mild silylating reagent MTBSTFA derivatives are 104 times more stable to hydrolysis than their corresponding TMS derivatives Produces easily interpreted mass spectra for GC/MS Addition of t-BDMCS catalyzes reactions of hindered alcohols and amines

Regis Technologies, Inc. partners with pharmaceutical and biotechnology companies to help expedite drugs to market. We offer unrivaled expertise in synthesis and separations services to advance your active pharmaceutical ingredients (API) from initial process development and scale-up development, to final validation and commercial manufacturing. From our extensive organic chemistry expertise and collegiate collaborations, we can deliver the added value of our innovative, proprietary chromatography products, especially those with a chiral emphasis. And, we continue to offer fine organic chemicals as we have for almost 50 years. So consider Regis an important partner in your drug development processes. We thrive on the challenges that these projects bring.